Established resistance mechanisms that induce AR reactivation include AR amplification, AR mutation, increased AR ligand availability, and the generation of constitutively active AR splice variants; however, a subset of tumors are able to progress without relying on ARs to proliferate, termed AR pathway-independent prostate cancer [12]. The gene discussed is AR; the disease is prostate carcinoma.